Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. (Q36086716)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

relapsing-remitting multiple sclerosis

19 March 2020

main subject

multiple sclerosis

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Xavier Montalban

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1

Ralf Gold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Ernst-Wilhelm Radue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Eva Havrdova

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Dusan Stefoski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Till Sprenger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Stanley Cohan

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Kimberly Umans

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Steven J Greenberg

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Gulden Ozen

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Jacob Elkins

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Gavin Giovannoni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

26 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

19 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4962457

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4962457

Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4962457

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4962457

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27461166

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27461166

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The IL-2/IL-2 receptor system: a target for rational immune intervention

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27461166

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S12883-016-0635-Y

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

19 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27461166%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

PubMed publication ID

27461166

1 reference